Computational Drug Development For Biologics Summit on October 14-16, 2025 in Boston, United States

The landscape of biologics discovery is rapidly evolving, driven by breakthroughs in AI, an influx of high-quality datasets, and regulatory momentum supporting in silico approaches. As industry leaders look to streamline R and D and de-risk development, there is a critical need for cutting-edge tools in modeling, characterization, screening, and developability.

Returning to Boston this fall at this opportune moment, the 10th anniversary of the CDD for Biologics Summit will unite 50+ decision-makers and industry experts from pharma and biotech to share their unfiltered lessons learned from validating and training computational models to streamline novel target validation, enhance biologics design and empower developability predictions.

This is the go-to forum for innovators across pharma and biotech to showcase current pipeline developments that can enable faster, smarter, and more scalable therapeutic design.

Diving into the latest industry applications of computational models, including physics-based, generative AI, and de novo design across multiple large molecules, including peptides, ADCs, bispecific T-cell engagers, multi-specifics, vaccines, and more.

URLs:
Tickets: https://go.evvnt.com/3115184-1?pid=10008
Brochure: https://go.evvnt.com/3115184-3?pid=10008

Time: 8:30 AM - 5:00 PM

Prices:

Conference + Pre-Conference AI Validation Workshop Day - Industry Pricing: USD 3297.00,

Conference + Pre-Conference AI Validation Workshop Day - Discounted Pricing: USD 2697.00,

Conference + Pre-Conference AI Validation Workshop Day: USD 4197.00,

Conference Only - Industry Pricing: USD 2499.00,

Conference Only - Discounted Pricing: USD 2099.00,

Conference Only - Service and Solution Provider Pricing: USD 3199.00

Speakers: Abhinav Gupta, Senior Scientist - Artificial Intelligence Innovation for Antibody, Sanofi, Andrew Wollacott, Sr. Director, Research, Visterra, Gabor Oroszlan, In Silico Lead, Project Manager, Senior Scientist, VRG Therapeutics, Gopal Karemore, Global Quantum Lead in Healthcare and Life Sciences, IBM, James Bowman, Senior Investigator and Director - Protein Engineeering, AI Proteins, Jenna Caldwell, Associate Principal Scientist, AstraZeneca, Jinbo Xu, Professor, Toyota Technological Institute at Chicago, Jing Wang, Director, Eli Lilly and Co., Joel Karpiak, Senior Director, Head of Protein Design and Informatics, GlaxoSmithKline, Kannan Sankar, Senior Expert - Data Science and Bioinformatics, Novartis, Mark Aquino, Principal Data Scientist II, AbbVie, Natnael Hamda, Associate Director AI ML Research Scientist (Early Drug Discovery), Astellas Pharma, Neeraj Agrawal, Director, Attribute Sciences, Process Development, Amgen, Norbert Furtmann, Head of AI Innovation - Large Molecules Research, Sanofi, Radoslav Enchev, Group Leader, The Francis Crick Institute, Ryan Emerson, SVP, Data Science and GM, Platform Solutions, A-Alpha Bio Inc., Shipra Malhotra, Senior Scientist - Biologics, Computational and Machine Learning, Takeda Pharmaceutical, Talip Uçar, Senior Director, AI Research, AstraZeneca, Yao Fan, Director - Protein Design and Optimization, Tectonic Therapeutic